ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Recommendation of “Buy” by Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $38.00.

Several equities research analysts recently commented on the company. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the fourth quarter valued at about $29,000. R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme during the fourth quarter valued at approximately $36,000. Bank of America Corp DE raised its holdings in shares of ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Ameriprise Financial Inc. purchased a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $85,000. Finally, Guggenheim Capital LLC acquired a new position in ABIVAX Société Anonyme in the 4th quarter worth approximately $92,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Up 3.2 %

Shares of NASDAQ:ABVX opened at $7.06 on Friday. The company has a 50 day moving average of $6.71 and a 200-day moving average of $8.59. ABIVAX Société Anonyme has a twelve month low of $5.50 and a twelve month high of $16.63.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.